These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24128669)

  • 21. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
    Wang T; Ueda Y; Zhang Z; Yin Z; Matiskella J; Pearce BC; Yang Z; Zheng M; Parker DD; Yamanaka GA; Gong YF; Ho HT; Colonno RJ; Langley DR; Lin PF; Meanwell NA; Kadow JF
    J Med Chem; 2018 Jul; 61(14):6308-6327. PubMed ID: 29920093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
    Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
    J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.
    Bouba Y; Berno G; Fabeni L; Carioti L; Salpini R; Aquaro S; Svicher V; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Antimicrob Chemother; 2020 Jul; 75(7):1778-1786. PubMed ID: 32160290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
    McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate.
    Wensel D; Gartland M; Beloor J; Shetty KN; Wolf J; Stewart E; Clark A; Tenorio A; Krystal M
    Antiviral Res; 2024 Sep; 229():105953. PubMed ID: 38960100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
    Gartland M; Zhou N; Stewart E; Pierce A; Clark A; Ackerman P; Llamoso C; Lataillade M; Krystal M
    J Antimicrob Chemother; 2021 Feb; 76(3):648-652. PubMed ID: 33241285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
    Hanna GJ; Lalezari J; Hellinger JA; Wohl DA; Nettles R; Persson A; Krystal M; Lin P; Colonno R; Grasela DM
    Antimicrob Agents Chemother; 2011 Feb; 55(2):722-8. PubMed ID: 21078951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
    Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
    J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.
    Lin PF; Blair W; Wang T; Spicer T; Guo Q; Zhou N; Gong YF; Wang HG; Rose R; Yamanaka G; Robinson B; Li CB; Fridell R; Deminie C; Demers G; Yang Z; Zadjura L; Meanwell N; Colonno R
    Proc Natl Acad Sci U S A; 2003 Sep; 100(19):11013-8. PubMed ID: 12930892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.
    Ho HT; Fan L; Nowicka-Sans B; McAuliffe B; Li CB; Yamanaka G; Zhou N; Fang H; Dicker I; Dalterio R; Gong YF; Wang T; Yin Z; Ueda Y; Matiskella J; Kadow J; Clapham P; Robinson J; Colonno R; Lin PF
    J Virol; 2006 Apr; 80(8):4017-25. PubMed ID: 16571818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
    Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
    J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
    Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
    J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.
    Nowicka-Sans B; Gong YF; McAuliffe B; Dicker I; Ho HT; Zhou N; Eggers B; Lin PF; Ray N; Wind-Rotolo M; Zhu L; Majumdar A; Stock D; Lataillade M; Hanna GJ; Matiskella JD; Ueda Y; Wang T; Kadow JF; Meanwell NA; Krystal M
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3498-507. PubMed ID: 22547625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
    J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
    Ratcliff AN; Shi W; Arts EJ
    J Virol; 2013 Jan; 87(2):923-34. PubMed ID: 23135713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.